Medical diagnostic company Shimadzu Medical Systems USA reported on Monday the receipt of the US FDA 510(k) clearance for the patient side conventional radiographic/fluoroscopic (RF) table system, FLUOROspeed X1.
With immediate market launch, the company's new radiographic/fluoroscopic (RF) FLUOROspeed X1 table system offers a high image quality and a multitude of features that improve work flow and operator efficiencies which contributes to lower cost of care.
A part of the FLUOROspeed series, the company's new FLUOROspeed X1 with its 665lb static patient weight and 500lb all motion weight, easily performs both bariatric and routine daily fluoroscopic and radiographic exams. It is practically priced and comes equipped with a 17"x17" dynamic digital X-ray detector (FPD) in the table bucky allowing be used for both fluoroscopy as well as radiographic exams.
The 31.5-inch aperture opening between table top and deck also provides access for imaging patients in wheelchairs as well as fits in smaller rooms. Adding the second X-ray tube on an overhead rail, the FLUOROspeed X1's functionality and versatility increases exponentially, concluded the company.
AnnJi Pharmaceutical secures FDA Fast Track Designation for AJ201 in rare neuromuscular disease
Myosin Therapeutics' MT-125 granted US FDA Fast Track designation in glioblastoma
Boehringer Ingelheim's JASCAYD (nerandomilast) IPF treatment gains Chinese regulatory approval
Galera Therapeutics sells dismutase mimetics portfolio to Biossil in USD108.5m agreement
Arcturus reports interim Phase 2 data for ARCT-032 in cystic fibrosis
Sanofi's efdoralprin alfa shows superior results in phase 2 study for AATD
FDA accepts Xspray Pharma's NDA for XS003 with PDUFA date set for June 2026
Citius Oncology and McKesson sign US distribution agreement for LYMPHIR
Cumberland Pharmaceuticals adds FDA-approved oral capsule for H. pylori to commercial portfolio
Genentech's Gazyva (obinutuzumab) receives US FDA approval to treat adults with lupus nephritis
AstraZeneca wins US FDA approval for Tezspire in chronic rhinosinusitis with nasal polyps
Antengene reveals ATG-022 clinical data at ESMO 2025
WeightWatchers launches RxFlexFund to expand affordable GLP-1 access for employers and employees